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Abstract 
In 2001 and 2004, two multinational companies (MNC) of the pharmaceutical industry, 
respectively Bayer and Janssen, left its manufacture operations in Portugal. From its exit, 
other two Portuguese small and medium enterprises (SME) were born: Bluepharma and 
Lusomedicamenta. These companies have been highly successful due to the 
representativeness of exports, contract-manufacturing and generic production. This report 
intents to study the exit of the MNC and the implementation of the Portuguese SMEs. 
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1 Case description 
Back in 2001, the German pharmaceutical company, Bayer, announced the closure of its 
Coimbra’s production plant. A group of four Portuguese saw this event as an opportunity to 
buy the industrial unit and establish a new company. Hence Bluepharma (BPh) was born. Its 
success is shown by its annual turnover growth of €3M in 2001 to roughly €18M in 2011 
(+83%; CAGR: 19.62%), [1] in sharp contrast with a CAGR of 6.72% for the worldwide 
pharmaceutical sales from 2003-2012. [2] In 2004, Janssen-Cilag (the pharmaceutical unit of 
Johnson & Johnson), also announced its intent to close its Portuguese plant. A group of the 
former Janssen’s Portuguese management team bought the industrial facilities (management 
buy-out – MBO), to, thus, create the Portuguese company Lusomedicamenta (LM). From 
2005 to 2010, LM grew in an average growth rate of 11%, [3] whereas the Portuguese drug 
sales grew at an average of 4% during the same period of time. [4] 
This report intents to (1) study and explore the conditions under which the Multinational 
companies MNC (Bayer and Janssen) had to leave Portugal, (2) study the factors underlined 
the successful implementation of the new Portuguese companies (BPh and LM) and, finally, 
(3) highlight strategies companies should adopt to keep-up with the demanding 
pharmaceutical industry. 
2 Understanding the differences between the business models 
Despite the fact that all four companies referred in this report operate in the pharmaceutical 
industry, there are some underlying differences that should be previously addressed. 
The MNCs are companies that have its business model centered in the discovery and 
commercialization of brand-name new drugs, under patent protection. When the patent 
expires, other companies can produce and commercialize the molecule, as long as it shows its 
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bioequivalence. These are the generic companies, like BPh and LM. These, besides 
producing generics, it also buys licenses to produce and commercialize brand-name drugs, 
after its patent is expired. Lastly, there is a third way by which these Portuguese companies 
operate. Alongside with the two-abovementioned practices, BPh and LM also produce, in its 
industrial plants, pharmaceutical forms (brand-name drugs or generics) to a third client, 
mostly international costumers – contract manufacturing.  
3 Literature review 
3.1 International Business Strategies 
A company’s entry and exit movements into and from a foreign country, relay at the heart of 
International Business strategies. Its motivations and entry modes are important to understand 
“why” did it decide to invest in a certain country. [5] Portugal’s FDI and exports incentives – 
especially from the 80s, upon Portugal’s adherence to EEC, until now – and access to “low-
cost” labor were two of the main drivers for the high inflow of FDI registered during the 80s 
decade in Portugal. [6] 
3.2 Challenges of the Pharmaceutical Industry in the XX century 
Traditionally, the global pharmaceutical industry was characterized by a rapid growth, high 
profits, and structural stability, despite showing disrupting innovation. However, companies 
were losing brand-name drug patent at a higher rate than these could be replaced, [7; 8] which 
led to the emergence of generic products. The highly regulated industry was demanding extra 
costs to guarantee the quality of its products, which aligned with lower margins resulting from 
fierce competition, the pharmaceutical industry started to consolidate and form strategic 
alliances. From 1986 to 1993 the number of strategic alliances in the pharmaceutical industry 
increased from 121 to over 400. [8] These challenges may be at the heart of the exit rationale 
behind the pharmaceutical MNCs that exited Portugal. 
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3.3 The arise of the pharmaceutical SMEs 
Parts of these alliances were with manufacturer pharmaceutical small and medium 
enterprises (SMEs), to which a company could outsource some of its production. [8] This could 
result in a lower risk for the contractor company as it didn’t need to heavily invest in 
production facilities, when demand for a specific product was, as seen by the emergence of 
generics, volatile. [9; 8] The flexibility provided by the SMEs, alongside with its innovatory 
capability, contributed for the important acknowledge of SMEs. [5; 8] reflected in ’11-’12 
growth of 62% registered at EMA. [10] Another important aspect of the SMEs is its export 
capability. [5] In Portugal, AICEP1 reunites all the conditions and incentives not only to 
attract foreign capital, but also to encourage the Portuguese companies, especially SMEs, to 
internationalize and export its products. [11] These incentives may be the reason for the 
successful implementation of the Portuguese companies. In association with AICEP, 
PharmaPortugal was created in 2005 with the objective of increase the exports associated 
with the pharmaceutical industry. [12] This project can depict the profile of both 
pharmaceutical Portuguese companies. 
4 Methodology 
In order to understand the entry and exit movements of the MNCs into and out of Portugal, 
and the success stories of the aforementioned Portuguese companies, it was initially 
performed an extensive literature review in regards to International Business, especially 
concerning the international production strategies. Moreover, it was of utmost importance to 
understand what were the economic conditions under which Portugal in during the following 
                                                
1 In 2007. the merger between Agência Portuguesa para o Investimento (API) and ICEP resulted in the creation of the 
Agência para o Investimento e Comércio Externo de Portugal (AICEP), the Portuguese governmental trade & investment 
agency. [11] 
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the events: (1) when the MNCs came to Portugal, (2) when the MNCs sold the industrial plants 
to the Portuguese companies, and (3) from that period until the present. Alongside with the 
Portuguese economy, it was indispensable to understand the trends and shifts within the 
pharmaceutical industry, both in Portugal and on a worldwide basis. Secondly, an extensive 
research in the companies’ websites, public journals and magazines was conducted in order to 
obtain information about its reasons and motivations to act the way they did. Since there is no 
systematic literature on this topic, the majority of the information used in this report is public, 
available in the aforementioned references. Finally, the support for the hypothesis generated 
to explain the movement of the companies was based on both the Industry analysis and 
company analysis. Some comparisons with other pharmaceutical companies were also done 
to support or reject the hypothesis generated. However, due to some information not being 
publicly available, some conclusions may be subject to further review. 
5 Part 1: Why did the Multinational Companies leave Portugal? 
Over the years we have witnessed the exit of important pharmaceutical MNC from Portugal; 
this is the case of Bayer and Janssen. The objective of this chapter is to understand the 
conditions under which these companies abandon Portugal, i.e. whether it was purely due to 
political and country-related events or conditions, or if it was due to a corporate strategy shift 
that led them to leave Portugal. 
5.1 The case of Bayer Pharmaceuticals 
The history of Bayer in our country started back in the IX century: in 1884, commercial 
agents from the German pharmaceutical started its the commercial activity in Portugal. Over 
the years, subsidiaries of Bayer were installed in Lisbon and other Portuguese cities, and the 
business evolved. It was only in 1972, through a greenfield [5;13] investment in Coimbra that 
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Bayer finished its plant facility – Centrofarma, which later changed its name to Bayer 
Portugal. [13] This move was in accordance with the Uppsala model, which states that the last 
stage of the internationalization process is the installation of a production facility. [5] The 
company had already some expertise and knowledge about the Portuguese secondary sector, 
which can be seen as a driver for their motivation: Bayer had already some production 
facilities in Portugal - anilines production integrated in the Chemist area of Bayer, which 
served the Portuguese textile industry; and it had some manufacturing plants to produce 
agriculture products, which served this sector. [13] Furthermore, during the late 70s and 80s, 
Portugal was economically preparing to enter the EEC, which was marked by the 
implementation of reforms to attract FDI to our country. The spread of faith of an improved 
country, alongside with a drop in export barriers to EEC countries, was also a motivation for 
Bayer to invest in Portugal. [6] The 60s, 70s and 80s were called the “Bayer’s golden years” in 
Portugal.2 The German company achieved huge visibility and exposure in Portugal, which 
Bayer had never seen before. [13] 
In 2001, Bayer’s Head Office in Germany announced a restructuring process  – it would 
now operate under a three-branch approach: (1) Bayer Healthcare (which includes 
Pharmaceuticals), (2) Bayer CropScience (which includes all of the agricultural segments) 
and (3) Bayer MaterialScience (which includes all kinds of other materials. from automobile 
to electronics). In the words of Dr. Manfred Schneider, then Bayer’s CEO, “The 
pharmaceuticals business is crucial to the performance of Bayer HealthCare. (…) We will 
therefore step up our restructuring program to improve efficiency and reduce costs, and adapt 
                                                
2 Not only Bayer Healthcare, which included the Pharmaceuticals, but all the business areas. 
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our structures to temporarily diminished growth expectations”. [14] Part of this restructuring 
program involved the closure of the Portuguese pharmaceutical plant.  
By this time, the pharmaceutical industry was turning its attention to SMEs, specialized in 
production, to which they could outsource the manufacturing of some of their products  (in a 
process called out-licensing), otherwise produced in Bayer’s plant. [15; 16] This process 
reduces the risk of investing significant capital for highly specific manufacturing facilities, to 
produce a particular product, which sales and returns of which may not compensate the initial 
investment. [9] 
Another hypothesis that can be discussed is the voluntary withdrawal of Lipobay®,3 the 
leading growth driver of Bayer’s Pharmaceuticals business, which had a heavy impact in the 
company stock price and results in 2001. [14] Since this was an oral solid formulation (pills), 
and assuming4 that Centrofarma only produced solid formulations, the loss of one of the most 
representative drugs, could eventually generate a break in the plant’s productivity. Besides 
that, in 2000, Bayer had expanded their solids plant in Bitterfeld, Germany, [14] which could 
hypothetically assure the production of the closed Portuguese plant. Or, in line with the 
former hypothesis, production could be outsourced to SMEs abovementioned. 
Alongside with these company rationales, the FDI incentives provided by the Portuguese 
government to MNCs did not meet the expectations created by ICEP, when they listed the 
pharmaceutical industry as being one of the major drivers for the Portuguese development. 
This lack of competitive incentives for MNCs linked with an intensification of regulatory 
                                                
3 Cerivastatin (Lipobay®) was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis 
that lead to kidney failure [17] 
4 Assumption made by the analysis of BPh portfolio that mostly consists in oral solid formulations, and the BPh website 
that states it “only” produces oral solid formulations. 
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issues and quality standards demanded at this time, [6; 8] may justify the concentration of 
manufacturing in some regions in order to control and certify the standards demanded by the 
European Union (EU) and the European Medicine Agency (EMA), which obviously are 
highly cost demanding. 
In this context, in 2001, after reading in the newspaper that Bayer was going to close their 
Portuguese plant, a group of four Portuguese entrepreneurs decided to buy Bayer’s Portuguese 
plant and. hence. BPh was born. [18] This move will be further discussed in chapter 5.2.  
5.2 The case of Janssen (Johnson & Johnson’s Pharmaceuticals) 
J&J entered the manufacturing business in Portugal more than a decade after Bayer 
constructed Centrofarma. In 1988, Cilag (the then Pharmaceutical branch of J&J), bought the 
Portuguese pharmaceutical company Laboratórios Medicamenta, creating Cilag-
Medicamenta.5 [19] Contrarily to the entry mode of Bayer, J&J decided to enter the Portuguese 
pharmaceutical market by acquiring an existing plant, manufacturer of pharmaceutical forms. 
The highly specialized labor in producing pharmaceutical forms already put in place by the 
previous company, was one of the drivers for their investment in Portugal. [5] By buying an 
active and certified pharmaceutical manufacturing plant, J&J was able to shorten the time-to-
market, as quality and control directives were already assured and certified, and labor was of 
the most qualified in the market (but without college education), and it was available at “low-
cost”. [6] 
Additionally, in 1988 Portugal had already been a member of the EEC for two years, which 
means that all the reforms to attract foreign capital were already in place together with the 
                                                
5 In 1995 the Belgian Janssen merged with Cilag resulting in “Janssen-Cilag Pharmaceuticals”. Later in 2010. Janssen-
Cilag was rebranded as Janssen. [20] 
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export incentives. This movement goes along with was happening in Portugal in this decade: it 
was also during this time that Portugal received the highest inflows of FDI in the 
manufacturing sector, contrarily to the service sector, which was what happen in other 
developed countries. [6] Following its purchase by J&J, the manufacturing plant continued 
its operational activity for 16 more years: in 2004, Janssen announced it would close its 
Portuguese plant, [21] just like Bayer had done 3 years before. The reasons behind this 
movement were (1) the fact that this manufacturing facility was prepared to produce small lots 
of a variety of pharmaceutical products, which no longer was the company’s core business; 
and (2) J&J also reached to the conclusion that it would be cheaper to assure the production 
under an outsourcing regime than to assume all the costs of manufacturing. [21] 
Janssen initially entered Portugal with the objective of producing “miniseries” or small lots of 
capsules, pills and syrups. All these products were produced by a specific order and in 
accordance with a chemical formulation developed by the company, answering small requests 
specific to some markets. However, the MNCs are abandoning this type of units, since they 
now needed to produce big lots, and carrying and financing these types of plants are not in their 
core business nor of interest to them, even because they are not going to produce to 
competitors. [21] 
Furthermore, in 2003 and 2004 the pharmaceutical industry was starting to experience 
unprecedented pressures. [8; 22; 23] Particularly in Janssen’s case, by 2005 it would lose the 
patent protection of a group of products that accounted for approximately 6% of revenues, [22] 
meaning they would be subjected to the generic sales hunt. However, another group of 
pharmaceutical products were approved in 2003 and 2004. These latter were formulations that 
could not be produced in Portugal, without a huge investment from J&J: its Portuguese plant 
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was equipped with state-of-the-art technology to produce oral solids, semi-solids and liquids,6 
but new products waiting for approval were mainly intravenous, transdermal and other sterile 
formulations, [24] which were not aligned with this plant production capability. Plus, 
Centocor, the manufacturing facility Janssen already had in Cork, Ireland,7 was undergoing a 
restructuring and growth program to produce more and new pharmaceutical products. [24] 
Additionally, acknowledging that outsourcing some of the product manufacturing would 
create a competitive advantage by lowering the cost of production, just like Bayer had done, 
can also explain the closure of the Portuguese plant that only produced small lots of products, 
and not their core ones. 
Furthermore, as previously referred in Bayer’s case, the FDI incentives in Portugal did not 
meet the expectations created by ICEP, and the regulatory and political regimes in Portugal 
were starting to become unstable and unpredictable environments, [9] making Ireland a better 
and more secure bet to invest in production. [25] Moreover the concentration of control and 
certification rationale to only one plant in one country instead of more than one, can also 
justify their decision to transition to Ireland. 
Hence, in 2004 after a negotiation period, Janssen Portugal’s management team bought out the 
plant with 100% Portuguese capital, leading to the creation of LM. [21] As in the case of BPh. 
this step will be discussed in chapter 5.2. 
                                                
6 Assumption made by analyzing the LM’s portfolio and website, as it states LM only produce oral solid, semi-solid and 
liquid formulations. 
7 Ireland is one of world’s countries where most Pharmaceutical companies have manufacturing operations. The low tax 
burden and the quality of work force are pointed as the major drivers to invest in Ireland. In 2008 more the 50% of Ireland 
total exports where in the pharmaceutical field. [9; 25] 
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5.3 Discussion notes 
After carefully analyzing these two cases, some similarities can be withdrawn. These may 
explain the exit of the MNC from Portugal – as one can see, a variety of factors contributed to 
the departure of these companies from Portugal, both company-specific and country-specific. 
1. The first hypothesis concerns their motivation to operate in Portugal: they both came 
to Portugal because they were attracted by the conditions delineated for the MNC 
operate in our country, despite some specific motivations (Bayer already knew the 
Portuguese manufacturing sector from past experience, for example). This is a strong 
hypothesis because during the 80s there was a high influx of FDI into Portugal, 
especially in the manufacturing sector. [6] 
2. The second hypothesis concerns one of the factors that made these companies leave 
Portugal: Over the years, the incentives provided by Portugal to MNC were not 
aligned with the expectations created by the ICEP. Plus, the technological sector was 
not the focus of the Portuguese government. [6] This created a lack of incentives for the 
MNCs to operate in Portugal. However, besides the abovementioned facts, the FDI in 
Portugal has been growing since 2000, registering an “increasing in industries and 
innovative activities and technological base turned for the international markets.” [26] 
As so, this hypothesis, per se, cannot explain their exit motivations. 
3. Another hypothesis that may explain their exit is that both companies underwent by a 
restructuring process, in which the products manufactured in the Portuguese plant 
were not their core business anymore. Although for Janssen this was one of the reasons 
indicated for their disinvestment, [21] for Bayer it was not possible to confirm that they 
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changed their core business. It is, however, possible to say that both decisions had a 
strategic managerial rationale behind.  
4. Finally, both companies realized that the out-licensing, and manufacturing SMEs 
were becoming an important player in the Pharmaceutical field, to which they could 
outsource some of their production. This was the other reason given by Janssen to 
abandon Portugal. [21] While for Bayer there isn’t information regarding this topic, the 
fact is that SMEs have emerged in Europe (and the World) at a high rate, [10; 27] which 
highlights their importance. 
6 Part 2: How successful are the newly formed Portuguese Pharmaceutical 
Companies? 
From the analysis of the previous chapter, one could think that the disappointment of one 
company in one industry would determine the disaster of the other companies that would 
take their place. In addition, Portugal is the country of the EU that has the highest rate of 
firm failure. [28] However that wasn’t the case for BPh and LM. Therefore, this chapter 
aims at highlight the factors that made (and make) them success cases in such turbulent 
times for both the industry and country in which they operate. 
6.1 The case of Bluepharma 
BPh was born after a group of four Portuguese entrepreneurs bought Bayer’s Portuguese plant, 
in Coimbra, in 2001. [29] As Bayer was going to leave Portugal, Paulo Barradas, a Portuguese 
pharmacist, saw an opportunity to buy the state-of-the-art industrial facility. [18] 
6.1.1 The opportunity: generics, contract manufacturing and out-licensing 
6.1.1.1 The generic’s Portuguese reality 
By 2001, the pharmaceutical industry was already facing major challenges, with the loss of 
patent protection of blockbuster drugs at a higher rate than they could be replaced, with the 
increasingly demanding regulatory issues, resulting in higher production costs, and with the 
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generics gaining their space in the market. [8] However, for the latter, the reality in Portugal 
was quite different: in 2000 and 2001 the consumption of generic drugs was nearly null, [9] 
compared with other countries where generic sales were 30% of the total drug sales, [30] 
namely USA and Germany where this percentage was more than 50%. [18] Taking this into 
account, the generic market was one of the bets of BPh – through BPh Genéricos -, as in 
Portugal the reality was very different from what was seen in other countries. 
6.1.1.2 Contract manufacturing and out-licensing activities 
At the same time, and as said in the previous chapter, the Big Pharma companies were turning 
their attention to smaller companies specialized in production, to which they could outsource 
some of their product manufacturing. [8] In this light of this, Bayer was BPh’s first client: 
Bayer contractually-agreed that it would continue to be BPh client for tree years,8 giving BPh 
time and stability to position in the market, perform R&D processes needed to develop a 
drug’s dossier (CTD format) and commercialize it (in an out-licensing perspective). [18] BPh’s 
out-licensing offer relies on the opportunity generated by the loss of patent protection: since a 
many drugs were losing their patent protection, they could in-license those expired patent and 
produce the brand-name drugs in their plant and export them to other countries. Portugal, as a 
member of the EU, could export to most of the European countries with almost no barriers. In 
2005, BPh began to sell other products aside from Bayer’s: they started to sell a niche 
antiepileptic generic (through BPh Genéricos branch), which sold more than the original; they 
also sold 60M pills of a cold medicine to France (Through BPh Indústria branch); and also 
began the production of an antidepressant. [18] 
                                                
8 This period was later increased to four years, because a tree-year period was very short to conclude all the phases for 
developing a drug. [18] 
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6.1.2 Financial incentives 
The incentives provided by Portugal (through ICEP) and the UE to SMEs and exporter 
companies were an important factor towards the decision to purchase Bayer’s manufacturing 
plant – 30% of BPh was bought with capitals from “PME Capital”. [1] However the specific 
incentives provided for the pharmaceutical industry, only appeared in 2005: PharmaPortugal 
in Portugal, [12] and a special program developed by EMA to help SMEs. [31] BPh also 
participated in several projects from QREN (Quadro de Referência Estratégica Nacional), 
oriented to innovation and development, and through them it is now internationally 
recognized. [32] The pharmaceutical industry is one of the most capital intensive, and access to 
capital is one of the most important drivers to R&D and, consequently, to growth. [16] 
Although the typical financing system, through loans, could eventually initiate the kick-off of 
the company, in the first years the returns would not compensate the initial offer, alongside 
with a high repayment risk associated. As so, UE play an important role in this field, as they 
offer financial aid and incentives to the  start of SMEs. [22] 
Hence, with the help of European funds, from 2001 to 2005, BPh grew from an annual 
turnover of almost €3M to almost €7M (+57%; CAGR: 18.47%), [1] while the Portuguese 
market grew at a CAGR of 4.33%, from 2003 to 2005. [4] Although these are not the exact 
same periods it is visible the extensive growth of the company without the external help of 
PharmaPortugal. This growth was mainly accomplished by the R&D projects that the 
company submitted and the representativeness their exports activity. 
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6.1.3 The export activity as a key success factor 
Like Hikma, a Jordanian pharmaceutical company, which has a production plant in Portugal, 
[34] BPh’s management also attributes their success to exports and contract manufacturing.9 
[35; 34; 36] An OECD report states that, “by 2010, sixteen pharmaceutical companies were 
exporting 81% of their production per year to over 60 countries, with high quality products and 
affordable pricing driving demand”. [37] This description is very similar to that of BPh, which 
in 2010, had more than €16M in revenues, where €12M (73%) were due to exports. [38] 
6.1.3.1 PharmaPortugal as a booster of internationalization 
In 2003, without ever having benefited from integrated structured project in the “export” 
segment, the Portuguese pharmaceutical industry was already positioned at the same level to 
other sectors that were beneficiating from this support, namely in internationalization: 
Household textiles - €861M; Port win - €323M; Pharmaceuticals - €293M. [39] However, 
though pharmaceutical exports were having a significant weight in the sector, its growth rate 
was slowing its pace, going from 53% in ’99-’00 to roughly 2% in ’02-’03. [39] This was the 
rationale behind the PharmaPortugal project. PharmaPortugal10 as a partnership between 
AICEP, INFARMED and APIFARMA, “is the brand name that identifies national exporting 
pharmaceutical companies and their products and communicates an image of European 
quality to the world”. [12] Integrated in this program, BPh could benefit from the incentives 
and aid and position itself in the international market as a quality and reliable medicine 
manufacturer. Inserted within this program, BPh saw its annual turnover grow from €7M in 
2005 to €18M in 2011 (CAGR: 14.44%), [1] against a CAGR of 0.70% for the national 
                                                
9 Interview available at http://sicnoticias.sapo.pt/programas/sucessopt/2013/07/08/sucesso.pt-06-07-2013 
10 PharmaPortugal initiative was able to duplicate the exports of pharmaceuticals in just 10 years: in 2011 the value of 
exports hit the €528M in pharmaceutical products, almost the double than in 2001. [40] 
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pharmaceutical industry for 2005 to 2010. [4] In 2009 its exports accounted for 60% of 
production, [41] whereas in 2012 this number outperformed the 80%. It would be interesting to 
have systematic data regarding its exports from 2001 to 2005, but this data was not available 
in the public data sources. The year of 2009 was also an important year for BPh, as it got the 
FDA approval to develop and produce solid formulations, becoming the first Portuguese 
pharmaceutical certified to export to the USA. [29] 
6.1.3.2 Drivers for innovation and expansion 
6.1.3.2.1 Luzitin – the fruit of collaborations 
Several articles refer that cooperation with other institutions will be one of the keys to success 
of Pharma companies, especially in what regards R&D processes. [7; 16] In fact, BPh has 
several collaborations and cooperation with other institutions. One of these collaborations 
with Universidade de Coimbra (and InovCapital capitals) originated a spin-off company: 
Luzitin. The Luzitins are proven to have antitumor activity in the Photodynamic Therapy 
field and clear advantages over the competitor products already on the market”. By now, 
the Luzitins are in clinical trials, and have strong perspectives of being in the market in 
2015, turning BPh into the second Portuguese pharmaceutical company to successively 
launch a drug in the market. 11 [42] 
6.1.3.2.2 Physical international expansion 
BPh is going to begin the construction of a new plant in Columbia. Part of this strategic 
decision is based in the fact that in Latin America is legal to industrially produce the generic 
version of a brand-name drug before the patent expires, without yet commercializing the 
product. This enables the company with an edge to make a reservoir of generics before it can 
                                                
11 The first Portuguese pharmaceutical company was Bial when it launched Zebinix® (Aptiom® in the USA), an 
antiepileptic drug. 
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be commercialized, reducing the time-to-market. In the words of Paulo Barradas, “this project 
may represent 5 to 10% of total revenues which in 2012 was of €32.5M”. [43] 
6.1.4 Bluepharma’s current position 
Through BPh Industria, the segment responsible for the exports, the group grew 50% in 2012 
against a 10% industry loss. [35; 44] Exports represent 82% of the company results, and its 
exports to more than 40 countries in Europe, USA, Africa, Australia, Middle East and Asia. [29; 
32; 35] Additionally, since its exports business has such a significant and positive impact on 
its results, the company is able to finance the production costs without the recourse to bank 
loans. [35] The success of the company led them to be awarded with “PME Excelência” 
(Excellence SME) for both 2011 and 2012, by IAPMEI; BPh also won the INSEAD 
Entrepreneurship 2011/2012 award, among other recognitions displayed in BPh’s website. 
[29] 
6.2 The case of Lusomedicamenta 
LM was born after the old Janssen-Cilag management team purchased the plant left by the 
American company in 2004. All the workers kept their job, with a little twist: they were going 
to produce drugs to other companies beside Janssen (which contractually agreed to be LM’s 
client for five years. just like in BPh and Bayer’s case. Janssen represented 55% of LM orders 
in 2005). [21] As also seen for the previous case, the fact that the former remained LM’s client 
for five years gave the Portuguese company a stable source of income and time to prepare its 
international expansion. Janssen perpetuated this agreement with LM in 2012: they both 
signed a significant contract for an annual production of 200M pills until 2016. [45] 
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6.2.1 The opportunity: contract manufacturing and out-licensing 
As seen in the previous case, there was an important acknowledgement by the Big Pharmas 
regarding the crucial role of SMEs for the success of this Big companies; this also created an 
opportunity for LM.  
6.2.1.1 Not pursuing the generic’s Portuguese market 
In 2005, the generic consumption in Portugal was starting to rise: the Government was 
creating incentives to increase the generic consumption in a way to decrease the Healthcare 
expenditures, in what regards the drug consumption. [9; 46] 
As so, with the rapid intensification of the generic market in Portugal, LM decided not to 
pursue this practice. This might have been a strategic move, as it could immediately start to 
chase the international market and the international players, almost entirely dedicating to 
exports. Plus, the generic companies in Portugal, as BPh, have to be extremely competitive in 
terms of pricing and market position, as small country like Portugal with just 10M habitants 
and a GDP per capita of €15,702.2 in 2012, [47] the domestic consumption, alongside with the 
intense competition, cannot hold up a company in the domestic market. 
6.2.1.2 Contract manufacturing and out-licensing activities 
In 2005, just one-year after the creation of LM, it had production agreements with more than 
150 brands in a total of 850 references, with the projection of producing more than 30M 
pillboxes,12 [21] which contrasts with Medinfar,13 another Portuguese pharmaceutical 
company that produces 12M units (in 2013) in it Farmalabor facility.14 [48] Exports accounted 
for 45% of the total produced by for 47 countries to which the plant is certified: Spain, France, 
                                                
12 With capacity to increase up to 40M units per year. [19] 
13 Medinfar Group is a Portuguese Pharmaceutical company that is in the Market since 1970. In 2000 it opened a 
subsidiary in Morocco to keep-up with international demand and expansion. [48] Medinfar is present in a variety of 
businesses, from Consumer Health, Biotechnology, Generics, Medical Devices, among others. In 2006 it had a global 
sales volume of €61M. [49] In 2011, this volume increased to €67M (+0.10%), where €3M represented exports. [45]  
14 However there is room to increase the capacity to 40M units per year. [48] 
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UK and Germany are the top destinations, but the company is also producing to Middle East, 
Canada and Brazil. LM not only dedicates to exports, but also to in-licensing products to sell in 
Portugal. The portfolio comprises all the pharmaceutical forms that the company produces, 
from solids and semi-solids to liquids. However, though it has a large portfolio regarding this 
practice, it represents only 35% of its business. [19; 46]  
6.2.2 Financial incentives 
Just like BPh, LM leveraged from the incentives provided by the Government, including the 
aid for PharmaPortugal right from the start. From 2005 to 2010 LM grew in an average growth 
rate of 11%, [3] whereas the Portuguese drug sales grew by an average of 4% in the same 
period of time; [4] in 2010, its sales volume grew to €50M – outperforming its initial 
expectations -,15 where 75% represented exports; [50] the Portuguese market, in contrast, 
suffered from a break of 2.5% between 2009 and 2010. [4] Hence, the aforementioned numbers 
clearly show how LM was able to outperform the Portuguese market. 
6.2.2.1 Drivers for innovation and expansion 
6.2.2.1.1 Focus in a niche market 
LM produces solids, semi-solids and liquids, and have in its portfolio Pharma giants like 
Novartis or Bayer. [19] The Bayer’s case is an interesting one, as it is also a client of BPh, as 
seen in the previous chapter. While one can argue that LM puts in place competitive prices that 
put BPh in a delicate position, it is more likely that LM produces the pharmaceutical forms that 
are not available in the BPh plant, such as semi-solids and liquids. 
In R&D companies the more specialized the company is in a particular disease or therapeutic 
category, the more likely it is to have success by leveraging in its expertise. [7; 9; 16] As so, it 
                                                
15 In 2009 LM bought the Seber manufacturing facilities in Póvoa de Santo Adrião. With this move LM was 
expecting to grow 25% from €32M to €40M sales in 2010. [50] 
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decided to specialize in one pharmaceutical form: effervescent pill. Specializing in niche 
products makes them an important and competitive player in the markets, and a reference in 
that type of formulation, which can help them to sustain its position. [16] Hikma also attributes 
part of its success by strategically concentrating one of its operations in a niche product: the 
cephalosporins – an anti-infective drug with similar uses to penicillins. This product 
accounted for 20% of sales in 1990 and 46% in 1996. [34] It would be interesting to have data to 
analyze and compare the companies’ market position for its niche product, but unfortunately 
there is no public data available regarding this topic.  
Just like BPh. another factor that makes this company so successful is the partnerships 
established by LM. These partnerships enable them to reach the latest technology and the most 
modern R&D processes. [16; 19] 
6.2.3 Lusomedicamenta’s current position 
In 2010 its revenues were of €50M of which 75% were exports. [51] In 2012, 65% of the 
company production is exported, against a 10% exports for the Medinfar Group [48] -, to more 
than 40 countries in the five continents. [19] It is interesting to analyze that the exports 
representativeness drop by 10% in 2 years. This may be due of an intensification of the SMEs 
all over Europe, [10] or due to the lack of accurate data, as one of the references regards an 
interview for a Portuguese newspaper and the other one regards the company website. Either 
way, in both cases exports represent the largest bulk of revenues. 
6.3 Discussion notes and main conclusions 
From the previous analysis, the two aforementioned cases outline a set of four interesting 
conclusions: 
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1. The implementation of their initial operation was largely due to the community 
incentives provided by the Portuguese government and EU. These funds allowed the 
companies to access capital needed to fund its R&D activities. Although not specific to 
the pharmaceutical industry, it may have a key role due to the intense capital 
requirements characteristics of this industry. As so, community funds may be said to 
be an important driver for the initial growth, but not the critical one. If this was 
decisional, all SMEs would have the “same” success, which is not the case. [28] 
2. Either in BPh or in LM case, its former companies, respectively Bayer and Janssen, 
agreed to be its clients, permitting the companies to establish in the market – national 
and international, by allowing the companies to have access to stable income during 
the kick-off stage. Together with conclusion 2, this may have been the key and 
differentiated factor for its successful implementation. 
3. Also, in both cases, the key success is the exporting activity. By acknowledging that 
Portugal was a small country with little capacity for domestic expansion and 
consolidation, both companies turned its eyes to foreign markets. Besides, its expertise 
in the business allowed them to understand possible outcomes of production 
partnerships with Big Pharma companies. However, the domestic market, including 
the generics, plays an important role in both companies revenues. However, in 
Medinfar’s case the exports activity only have a 10% representation in its €64M 
revenues in 2012. [48] As so, other areas aside from exports may become also important 
in these companies business models. 
4. Price pressures and political instability felt in Portugal in the latest years had little 
effect in these companies, due to the weight of its export activity. [35; 50] Nevertheless, 
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there are reasons to believe that if this pressure assumes tighter contours, the domestic 
activity may become unsustainable to these, and other, companies. [48] 
7 Part 3: What will be the future for the Portuguese Pharmaceutical Companies? 
In the previous chapters it was shown how the failure of one company can become the fortune 
of another, through the success cases of BPh and LM. Nevertheless, given the “fast-change” 
and reinvention nature of this industry, it is important to look upon the future of these 
companies. As so, the objective of this chapter is to assess the three major future trends, and 
how these companies can or should adapt to them. 
7.1 Price pressures and tighter regulatory policies will continue  
Price pressures and regulatory policies are topics that were present throughout this report, as 
being two of the biggest drivers to companies lower margins and the need for restructuring: 
with higher costs, the price pressures reflect lower margins and, thus, lower profits. [52] The 
Portuguese government announced that the drug prices would decrease, again, in 2014 [53] 
However, after further consideration,  decided to maintain the price for the generic drugs. [54] 
This continuous price instability already led Bial to delay the production of a new drug 
developed by this company, for at least two years. [55] Although there isn’t much that 
companies can do to run from these reforms,  should continue to explore international markets 
rather than the domestic market. The higher the prone towards exports and diversification, the 
more likely  are to overcome this domestic instability.  
7.2 Emergence of manufacturing SMEs – the rise of the competition 
The importance of SMEs as drivers to innovation for the pharmaceutical industry is starting to 
show some results. As said in previous chapters, the number of companies registered as SMEs 
with EMA increased 62% from 2011 to 2012. [10] The Indian pharmaceutical industry is 
estimated to have 9.456 units in the SME, which account for around 87% in production by 
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volume. [27] Although these numbers clearly show the acknowledgment of these companies, it 
also shows that competition is fiercely arising. As so, to protect themselves, companies 
should specialize in niche products and markets in order to leverage from its expertise. 
7.3 Emergent economies  
Emerging markets offer the biggest growth opportunities for the pharmaceutical industry, 
once its market share is set to rise to almost 40% by 2016, although with smaller margin. [81] 
BPh and LM are already exporting to emergent markets, like Venezuela and Columbia. 
Another country in which BPh and LM should focus is the Angolan, where the drug market is 
one of their strategic focus. [56]   
8 Conclusion 
The objective of this report was to clearly highlight the key success factors that make BPh and 
LM two admired companies, born after an apparent failure from two MNC. The major driver 
of its success has to be attributed to the exports of its products. However, due to lack of 
systematic information some additional information would be needed to better support some 
affirmations.. 
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